American CryoStem Corporation (OTCMKTS:CRYO) Stock Continues to Move Up: Jumps 15% In a Week

If you are currently looking into stocks which have managed to record handsome gains in recent day then it might be a good move to take a look at the American CryoStem Corporation (OTCMKTS:CRYO) stock. Yesterday, the stock continued to be in focus and ended up with gains of 5% for the day.

Trading Data

On Wednesday, CRYO stock ended up by 4.66% to $0.8195 with more than 82k shares, compared to its average volume of 139k shares. The stock has moved within a range of $0.7990 – 0.8695 after opening trade at $0.8010.

Completion of Patient Recruitment for its Post-Concussion Syndrome (PCS) ATCELL(TM) Phase I Clinical Trial

However, it should be noted that the biotech company has seen its stock clock gains of as much as 15% over the course of the past week. Yesterday, the American CryoStem stock came into focus among investors after it made an announcement with regard to the fact that it had concluded the recruitment of subjects in relation to the Phase 1 clinical trial for an Investigational New Drug.

The trial in question is in relation to study of the product and its effect on post-concussion syndrome. It goes without saying that it was a major announcement from the company and investors seemed to have been suitably excited about the prospects as well.

In light of the strong rally in the stock over the past week, it may now be a good move for investors to add the American CryoStem to their watch lists and keep an eye on the price action.

Key Quote

Principal Investigator, Peter Hanson, MD stated, “I would like to thank our team for all their hard work in successfully recruiting all participants for this study. In light of the recruitment difficulties many studies are experiencing during the pandemic, their dedication and effort has paid off. We look forward to begin participant treatments in the near future.”

Technical Data

CRYO stock is above the 20-Day and 50-Day Moving averages of $0.7858 and $0.5797 respectively. Moreover, the stock is above the 200-Day moving average of $0.4436.